UltraSPECT signs multi-year deal with UPPI

Justine Varieur Cadet | | Health Imaging | Molecular Imaging
UltraSPECT, a developer of nuclear medicine image reconstruction technology, has signed a multi-year distribution agreement with nuclear pharmacy network UPPI for the exclusive leasing and/or non-exclusive sale of its cardiac and bone imaging applications in the U.S.

The Auburndale, Mass.-based company said the product line utilizes its Wide-Beam Reconstruction (WBR) technology that seeks to enhance the performance of gamma cameras and PET scanners.

Justine Varieur Cadet

Related Content

Dementia cases are about to skyrocket—how will this affect imaging demand?
Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.